Explore

Trendline Trendline
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead
Trendline Trendline
ATB Therapeutics Appoints Mark Throsby as CEO to Drive Growth

ATB Therapeutics Appoints Mark Throsby as CEO to Drive Growth

ATB Therapeutics Appoints Mark Throsby as CEO to Drive Growth
Trendline Trendline
Orca Bio Appoints Bijan Nejadnik, M.D., as Chief Medical Officer to Drive Clinical Strategy

Orca Bio Appoints Bijan Nejadnik, M.D., as Chief Medical Officer to Drive Clinical Strategy

Orca Bio Appoints Bijan Nejadnik, M.D., as Chief Medical Officer to Drive Clinical Strategy
Trendline Trendline
TRIANA Biomedicines Appoints Mohan Bala as COO, Expands Scientific Advisory Board

TRIANA Biomedicines Appoints Mohan Bala as COO, Expands Scientific Advisory Board

TRIANA Biomedicines Appoints Mohan Bala as COO, Expands Scientific Advisory Board
Trendline Trendline
Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts
Trendline Trendline
Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development
Trendline Trendline
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase
Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth
Trendline Trendline
Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins
Trendline Trendline
Palatin Technologies to List on Nasdaq, Aiming for Enhanced Visibility and Liquidity

Palatin Technologies to List on Nasdaq, Aiming for Enhanced Visibility and Liquidity

Palatin Technologies to List on Nasdaq, Aiming for Enhanced Visibility and Liquidity
Rapid Read Rapid Read
Aspera Biomedicines Advances Cancer Research with SpaceX ISS Mission

Aspera Biomedicines Advances Cancer Research with SpaceX ISS Mission

Aspera Biomedicines has successfully launched its second ADAR1p150 protein crystallization experiment to the International Space Station (ISS) aboard SpaceX CRS-34. This mission aims to advance the development of an oral formulation of Rebecsinib, a therapeutic targeting cancer stem cells. The experiment utilizes Redwire Corporation's Pharmaceutical In-space Laboratory (PIL-BOX) technology to crystallize proteins in microgravity, providing structural insights that are unattainable on Earth. These insights are crucial for improving drug formulations and broadening patient access. The mission builds on Aspera's previous experiment and is funded by NASA's In Space Production Applications (InSPA) Phase 2 award.
Trendline Trendline
Faruqi Faruqi, LLP Alerts Immutep Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Immutep Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Immutep Investors of Securities Class Action Deadline